The Viatris Pacira acquisition buys two US pain products, Exparel and Zilretta, for $36.50 per share in cash. That values Pacira BioSciences at $1.65 billion. Viatris announced the agreement on 8 October 2026. It expects the deal to close by the end of 2026. Closing still needs a majority of Pacira shares to be tendered and the US antitrust waiting period to expire.
The lasting question is what Viatris is actually getting, and what could change that. This article sets out the assets, the deal mechanics and the open risks in the Viatris Pacira acquisition. It also covers the UK position, which the announcement does not address by name.
What does the Viatris Pacira acquisition buy?
Exparel is a long-acting local analgesic for post-surgical pain. Its active ingredient is bupivacaine, in a liposome injectable suspension. Zilretta is an extended-release steroid injection into the joint for osteoarthritis knee pain. The FDA approved it in 2017. The release also lists PCRX-201, a locally administered gene therapy for knee osteoarthritis, which is in Phase 2.
Pacira reported 2025 net product sales of $575.1 million for Exparel and $116.6 million for Zilretta. Those figures come from its full-year results, published on 26 February 2026. Exparel sales rose 5 per cent on 2024. Zilretta sales fell 1 per cent, but rose 4 per cent to $32.6 million in the second quarter of 2026.
The latest quarter shows steady but modest growth. Exparel sales were $147.8 million in the second quarter of 2026, up 3 per cent. Pacira said volume grew 4 per cent. A shift in vial mix and wider group purchasing organisation discount contracts offset part of that growth. On 4 August Pacira reiterated its 2026 Exparel guidance of $600 million to $620 million.
The price, the premium and the trailing revenue
Neither company disclosed a premium for the Viatris Pacira acquisition. BioSpace reported that Pacira closed at $25.20 the day before the announcement. On LSDN arithmetic, the $36.50 offer is a 44.8 per cent premium to that close.
The release states trailing revenue of about $746 million and adjusted EBITDA of about $177 million. Both cover the twelve months to 30 June 2026. Pacira sold its iovera device business to Zimmer Biomet on 31 July 2026. The release does not say whether the $746 million includes iovera, which added $24.2 million of sales in 2025. On LSDN’s reading, the trailing figure may include revenue that Viatris will not own.
Scale matters too. Pacira’s trailing revenue equals about 5 per cent of the $14.75 billion midpoint of Viatris’s 2026 revenue guidance. That is LSDN arithmetic. Viatris set that guidance on 6 August.
How is the deal structured, and when will it close?
Viatris will launch a tender offer for all Pacira shares. A second-step merger at the same price will follow for any shares not tendered. Pacira would then become a wholly owned Viatris subsidiary and leave the Nasdaq. The release says the tender offer has not yet started. It gives no launch date.
The merger agreement, filed in a Form 8-K dated 8 October, sets the conditions. More than 50 per cent of Pacira shares must be tendered. Viatris cannot waive that minimum without Pacira’s written consent. The US Hart-Scott-Rodino waiting period must also expire. Filings are due within 15 business days of signing.
The offer is not subject to a financing condition. Viatris plans to fund the deal mainly from excess cash, with the rest from short-term borrowings. It expects minimal impact on its gross leverage ratio. That ratio stood at 2.9 times at the end of the second quarter. Both boards approved the deal unanimously. Pacira’s board recommends that shareholders tender.
Either party can terminate if the offer is not completed by 8 April 2027. That date moves automatically to 8 July 2027 if only the antitrust and legal-restraint conditions remain open. Pacira would owe Viatris $62 million in specified circumstances, such as accepting a superior offer.
The Viatris Pacira acquisition is priced as a single cash figure per share. Many licensing deals instead split payment into upfronts, milestones and royalties. LSDN’s guide to biotech deal structure explains the difference.
Why does Viatris want non-opioid pain products?
Viatris says the Pacira products are synergistic with its fast-acting meloxicam opportunity. In the release, chief executive Scott A. Smith called the deal “an important step in advancing our strategy.” That strategy is to build the company’s innovative medicines business. Viatris also said it expects the deal to be immediately accretive to its financial guidance metrics.
Fast-acting meloxicam, coded MR-107A-02, is an investigational oral non-opioid for moderate-to-severe acute pain. On 18 May 2026 Viatris said the FDA had accepted the NDA for review. The filing used the 505(b)(2) pathway. The PDUFA goal date is 27 December 2026. No regulator has approved the drug.
The NDA rests on two randomised Phase 3 trials. One followed herniorrhaphy (NCT06215859, 579 patients). The other followed bunionectomy (NCT06215820, 410 patients). Both included a tramadol arm to confirm the pain model was sensitive. The primary endpoint was the summed pain intensity difference over 0 to 48 hours versus placebo. Viatris said the drug met primary and secondary endpoints in both trials.
LSDN’s FDA drug approval decisions tracker lists the 27 December date. A decision falls just before the deal’s targeted close. Viatris has not said how it would sell the two product sets together.
Analyst views are limited. BioSpace quoted Oppenheimer as calling the deal “strategically sound and fairly priced.” It added that Oppenheimer projects peak fast-acting meloxicam sales of up to $500 million. BioSpace also reported that Viatris expects more than $50 million of cost synergies by the end of 2028. LSDN found both figures in BioSpace alone.
What could weaken Exparel’s revenue?
Exparel faces generic entry on a negotiated timetable. In April 2025 Pacira settled US patent suits with Fresenius Kabi, Jiangsu Hengrui and eVenus. Fresenius may sell volume-limited generic product from a confidential date in early 2030. Pacira said the generic share starts in the high single digits of US volume.
That share rises to the low thirties per cent by 2033. It reaches the high thirties for the final three years of the agreement. Unlimited generic sales cannot start before 2039. Pacira said the last-to-expire Orange Book-listed Exparel patent expires on 2 July 2044.
Two further cases were filed on 26 November 2025. The defendants are The WhiteOak Group and Qilu Pharmaceutical (Hainan), in the District of Delaware. Pacira said the suits triggered a 30-month stay on final FDA approval of their generic applications. LSDN could not confirm the cases’ current status from the filings it read on 9 October. BioSpace reported that Pacira is still litigating against two other drugmakers.
Does the Viatris Pacira acquisition affect the UK?
Exparel is authorised in Great Britain. The emc lists two presentations, 133 mg in 10 mL and 266 mg in 20 mL. The marketing authorisation holder is Pacira Ltd, of Bourne End, Buckinghamshire. The licence numbers are PLGB 34175/0003 and PLGB 34175/0004 respectively. Both were first authorised on 1 January 2021.
The UK indications are specific. They cover adults as a brachial plexus block or femoral nerve block. They also cover adults and children aged six years or older as a field block. That block treats somatic post-operative pain from small to medium surgical wounds. The SmPC text on emc was last revised on 2 November 2022.
Viatris says it expects to expand the products’ reach across selected markets within its international infrastructure. The release does not name those markets or mention the UK. Whether the UK licence holder changes after closing is therefore not yet known.
What happens next in the Viatris Pacira acquisition?
Several dated events will settle how the Viatris Pacira acquisition plays out. Viatris must launch the tender offer and file for antitrust clearance. The FDA must act on fast-acting meloxicam by 27 December 2026. Closing is targeted by the end of the year. The contractual outside date is 8 April 2027.
Until then the answer to what Viatris is buying stays partly open. In the Viatris Pacira acquisition, the core Exparel and Zilretta revenues are documented. The effect of generic competition after 2030 is only partly quantified. The value of the meloxicam link depends on an FDA decision that has not yet been made.
